The Association between PON1 (Q192R and L55M) Gene Polymorphisms and Risk of Cancer: A Meta-Analysis Based on 43 Studies
Table 4
Results of meta-analysis for PON1-L55M polymorphism and cancer risk.
Variables
Case/control
M vs. L
MM vs. LL
ML vs. LL
ML+MM vs. LL
MM vs. ML+LL
OR(95% CI)
I2(%)
OR(95% CI)
I2(%)
OR(95% CI)
I2(%)
OR(95% CI)
I2(%)
OR(95% CI)
I2(%)
Total
8565/9996
1.277(1.127-1.448)
0
81.6
1.507(1.205-1.885)
0
68.5
1.192(1.064-1.337)
0.001
50.6
1.288(1.120-1.480)
0
70.9
1.417(1.176-1.708)
0
64.2
Breast cancer
1882/1731
2.186(1.438-3.323)
0
92.5
3.215(1.756-5.886)
0
81.8
1.579(1.145-2.177)
0.01
69.9
2.110(1.397-3.188)
0
85.3
2.727(1.563-4.756)
0
81.9
Gastrointestinal cancer
1803/2495
1.111(0.898-1.375)
0.071
50.7
1.165(0.848-1.601)
0.988
0
1.097(0.794-1.515)
0.023
61.5
1.120(0.829-1.512)
0.032
59.0
1.185(0.881-1.594)
0.996
0
Prostate cancer
2259/2888
1.233(0.971-1.566)
0
84.3
1.496(0.876-2.556)
0
85.5
1.291(1.071-1.557)
0.144
44.6
1.341(1.024-1.756)
0.008
74.6
1.284(0.838-1.966)
0.002
80.5
Hematologic tumor
1259/1187
1.271(1.059-1.525)
0.121
52.7
1.514(1.178-1.946)
0.376
0
1.212(0.954-1.540)
0.172
43.1
1.299(1.017-1.661)
0.124
52
1.405(1.111-1.778)
0.622
0
Ovarian cancer
377/553
1.219(0.965-1.539)
0.450
0
1.208(0.648-2.253)
0.393
0
0.833(0.536-1.296)
0.579
0
0.952(0.623-1.454)
0.802
0
1.482(0.800-2.743)
0.316
13.2
Lung cancer
579/418
1.095(0.666-1.801)
0.104
62.2
0.781(0.344-1.771)
0.404
0
1.074(0.711-1.622)
0.215
34.8
1.089(0.670-1.767)
0.146
52.7
0.806(0.361-1.799)
0.432
0
Other cancers
406/724
0.932(0.753-1.155)
0.333
12.6
0.884(0.505-1.548)
0.215
31
0.907(0.682-1.206)
0.801
0
0.910(0.696-1.190)
0.625
0
0.930(0.584-1.481)
0.252
25.4
Ethnicities
Caucasian
3616/4392
1.231(1.028-1.474)
0
83.8
1.737(1.519-1.986)
0
72
1.170(1.034-1.324)
0.199
22.4
1.334(1.215-1.465)
0
70.7
1.407(1.092-1.813)
0
67.8
Asian
2257/2667
1.604(1.089-2.363)
0
80.7
2.093(1.295-3.381)
0.441
0
1.550(0.995-2.417)
0.000
79.7
1.624(1.041-2.535)
0
80.8
1.967(1.238-3.125)
0.656
0
Mixed
2692/2937
1.177(1.004-1.379)
0.019
63.1
1.137(0.955-1.354)
0.088
47.8
1.112(0.953-1.297)
0.268
22.1
1.126(1.006-1.261)
0.165
36.3
1.262(0.957-1.665)
0.034
58.4
Control source
Population based
5787/6158
1.325(1.085-1.618)
0
88.7
1.568(1.091-2.253)
0
81.9
1.275(1.051-1.548)
0.401
4.5
1.275(1.051-1.548)
0
75.7
1.503(1.110-2.034)
0
80.5
Hospital based
2778/3838
1.240(1.056-1.456)
0
68.9
1.531(1.199-1.955)
0.132
29.8
1.255(1.020-1.543)
0.000
62.3
1.288(1.120-1.480)
0
66.7
1.411(1.173-1.698)
0.324
11.6
Genotype method
PCR-RFLP
4376/4698
1.243(1.053-1.466)
0
82.2
1.571(1.183-2.087)
0
70.1
1.164(1.033-1.311)
0.145
26.5
1.246(1.045-1.487)
0
69.3
1.483(1.167-1.884)
0
62.7
TaqMan
4189/5298
1.330(1.091-1.622)
0
79.5
1.309(0.988-1.735)
0.091
41.4
1.307(1.026-1.665)
0.001
71.5
1.370(1.073-1.748)
0
74.7
1.264(0.986-1.620)
0.05
48.5
Notes: statistically significant (P<0.05); P : P value of Q test for heterogeneity test; I2: 0%–25% means no heterogeneity, 25%–50% means modest heterogeneity, and 50% means high heterogeneity. Abbreviations: CI, confidence interval; OR, odds ratio; PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism.
